High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Immunologic Research

Volumn 47, Issue 1-3, 2010, Pages 65-77

  Luznik, Leo ^a   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone marrow transplantation; Cyclophosphamide; Graft versus host disease; Graft versus leukemia effect; Human leukocyte antigens; T lymphocytes

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TUMOR VACCINE; VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADRENAL DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; AUTOIMMUNE DISEASE; BRAIN DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HLA MATCHING; HOST CELL; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LYMPHOMA; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OPPORTUNISTIC INFECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; T LYMPHOCYTE; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; PROCEDURES; TRANSPLANTATION TOLERANCE;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MIDDLE AGED; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953959027     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8139-0     Document Type: Review

References (59)

1. MT Little 2002 Storb R: history of haematopoietic stem-cell transplantation Nat Rev Cancer 2 231 238 10.1038/nrc748 11990860
2. DWH Barnes MJ Corp JF Loutit FE Neal 1956 Treatment of murine leukaemia with X-rays and homologous bone marrow. Preliminary communication Br Med J 2 626 10.1136/bmj.2.4993.626 13356034
3. PL Weiden N Flournoy ED Thomas, et al. 1979 Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N Engl J Med 300 1068 1073 34792
4. MM Horowitz RP Gale PM Sondel, et al. 1990 Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 555 562 2297567
5. C Anasetti PG Beatty R Storb, et al. 1990 Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma Hum Immunol 29 79 91 10.1016/0198-8859(90)90071-V 2249952 (Pubitemid 20357658)
6. R Szydlo JM Goldman JP Klein, et al. 1997 Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings J Clin Oncol 15 1767 1777 9164184
7. Y Reisner N Kapoor D Kirkpatrick, et al. 1981 Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells Lancet 2 327 331 10.1016/S0140-6736(81)90647-4 6115110
8. HG Prentice HA Blacklock G Janossy, et al. 1984 Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients Lancet 1 472 476 10.1016/S0140-6736(84)92848-4 6142207
9. VT Ho RJ Soiffer 2001 The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood 98 3192 3204 10.1182/blood.V98.12.3192 11719354
10. R Storb ED Thomas 1985 Graft-versus-host disease in dog and man: the seattle experience Immunol Rev 88 215 238 10.1111/j.1600-065X.1985.tb01160.x 3910558
11. RL Powles HM Clink D Spence, et al. 1980 Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation Lancet 1 327 329 10.1016/S0140-6736(80)90881-8 6101787
12. R Storb HJ Deeg V Farewell, et al. 1986 Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease Blood 68 119 125 3521761 (Pubitemid 16041720)
13. JW Fay JR Wingard JH Antin, et al. 1996 FK506 (Tacrolimus) monotherapy for prevention of graft-versus- host disease after histocompatible sibling allogenic bone marrow transplantation Blood 87 3514 3519 8605372
14. J Liu J Farmer WS Lane, et al. 1991 Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 807 815 10.1016/0092-8674(91)90124-H 1715244
15. B Bolwell R Sobecks B Pohlman, et al. 2004 A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant 34 621 625 10.1038/sj.bmt.1704647 15300236 (Pubitemid 39341543)
16. C Cutler S Li VT Ho, et al. 2007 Extended follow-up of methotrexate-free immunosuppression using sirolimus and Tacrolimus in related and unrelated donor peripheral blood stem cell transplantation Blood 109 3108 3114 17138818
17. RA Nash L Johnston P Parker, et al. 2005 A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 11 495 505 10.1016/j.bbmt.2005.03.006 15983549 (Pubitemid 40862446)
18. V Ratanatharathorn RA Nash D Przepiorka, et al. 1998 Phase III study comparing methotrexate and Tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92 2303 2314 9746768
19. MK Jenkins RH Schwartz DM Pardoll 1988 Effects of cyclosporine A on T cell development and clonal deletion Science 241 1655 1658 10.1126/science. 3262237 3262237
20. MK Jenkins CA Chen G Jung DL Mueller RH Schwartz 1990 Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody J Immunol 144 16 22 2153162
21. Y Li XC Li XX Zheng, et al. 1999 Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance Nat Med 5 1298 1302 10.1038/15256 10545997 (Pubitemid 29535608)
22. WE Beschorner AD Hess CA Shinn GW Santos 1988 Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease Transplantation 45 209 215 10.1097/00007890-198801000-00043 3257308
23. GW Santos AD Hess GB Vogelsang 1985 Graft-versus-host reactions and disease Immunol Rev 88 169 192 10.1111/j.1600-065X.1985.tb01158.x 3910556
24. JE Wagner JS Thompson SL Carter NA Kernan 2005 Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial Lancet 366 733 741 10.1016/S0140-6736(05)66996-6 16125590 (Pubitemid 41207235)
25. M Eapen BR Logan DL Confer, et al. 2007 Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival Biol Blood Marrow Transplant 13 1461 1468 10.1016/j.bbmt.2007.08.006 18022576 (Pubitemid 350091382)
26. A Bacigalupo T Lamparelli F Gualandi, et al. 2001 Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study Blood 98 3174 10.1182/blood.V98.10.3174
27. R Schwartz W Dameshek 1959 Drug-induced immunological tolerance Nature 183 1682 1683 10.1038/1831682a0 13666859
28. MC Berenbaum 1963 Prolongation of homograft survival in mice with single doses of cyclophosphamide Nature 200 84 10.1038/200084a0 14074645
29. GW Santos AH Owens 1966 Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents Nature 210 139 140 10.1038/210139a0 5962069
30. H Mayumi K Himeno N Tokuda K Nomoto 1986 Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide- induced tolerance in an H-2 haplotype-identical strain combination Transplant Proc 18 363 369 3515673
31. M Eto H Mayumi Y Tomita, et al. 1990 Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion J Immunol 145 1303 1310 2143514 (Pubitemid 20255030)
32. H Mayumi M Umesue K Nomoto 1996 Cyclophosphamide-induced immunological tolerance: an overview Immunobiology 195 129 139 8877390
33. L Luznik S Jalla LW Engstrom R Iannone EJ Fuchs 2001 Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide Blood 98 3456 3464 10.1182/blood.V98.12. 3456 11719388
34. L Luznik PV O'Donnell HJ Symons, et al. 2008 HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 641 650 10.1016/j.bbmt.2008.03.005 18489989 (Pubitemid 351664058)
35. K Nomoto M Eto K Yanaga Y Nishimura T Maeda 1992 Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A J Immunol 149 2668 2674 1401906
36. M Mielcarek PJ Martin W Leisenring, et al. 2003 Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 756 762 10.1182/blood-2002-08-2628 12663454 (Pubitemid 36842003)
37. LM Burroughs PV O'Donnell BM Sandmaier, et al. 2008 Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma Biol Blood Marrow Transplant 14 1279 1287 10.1016/j.bbmt.2008.08.014 18940683
38. MP Devetten PN Hari J Carreras, et al. 2009 Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma Biol Blood Marrow Transplant 15 109 117 10.1016/j.bbmt.2008.11.011 19135949
39. Y Kanda S Chiba H Hirai, et al. 2003 Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000) Blood 102 1541 1547 10.1182/blood-2003-02-0430 12714500 (Pubitemid 36988069)
40. Kasamon YL, Luznik L, Leffell MS et al.: Nonmyeloablative HLA-haploidentical BMT with high-dose post-transplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 (Epub ahead of print).
41. SJ Pocock SE Assmann LE Enos LE Kasten 2002 Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems Stat Med 21 2917 2930 10.1002/sim.1296 12325108
42. RC Ash MM Horowitz RP Gale, et al. 1991 Bone marrow transplantation from related donors other than HLA- identical siblings: effect of T cell depletion Bone Marrow Transplant 7 443 452 1873591
43. EW Petersdorf TA Gooley C Anasetti, et al. 1998 Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient Blood 92 3515 3520 9808542
44. T Sasazuki T Juji Y Morishima, et al. 1998 Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan marrow donor program N Engl J Med 339 1177 1185 10.1056/NEJM199810223391701 9780337 (Pubitemid 28482126)
45. Y Morishima T Yabe K Matsuo, et al. 2007 Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor Biol Blood Marrow Transplant 13 315 328 10.1016/j.bbmt.2006.10.027 17317585
46. + T cells do not induce graft-versus-host disease J Clin Invest 112 101 108 12840064
47. + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease Blood 111 2476 2484 10.1182/blood-2007-08-109678 18045967 (Pubitemid 351451463)
48. BJ Chen X Cui GD Sempowski C Liu NJ Chao 2004 Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease Blood 103 1534 1541 10.1182/blood-2003-08-2987 14551132 (Pubitemid 38168675)
49. L Luznik JE Slansky S Jalla, et al. 2003 Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras Blood 101 1645 1652 10.1182/blood-2002-07-2233 12406877 (Pubitemid 36182546)
50. BR Dey S McAfee C Colby, et al. 2005 Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation Br J Haematol 128 351 359 10.1111/j.1365-2141.2004.05328.x 15667537 (Pubitemid 40216157)
51. + T cells J Immunol 175 665 676 16002661
52. Symons HJ, Levy MY, Wang J et al.: The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2010;14:499-509.
53. WI Bensinger PJ Martin B Storer, et al. 2001 Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers N Engl J Med 344 175 181 10.1056/ NEJM200101183440303 11172139 (Pubitemid 32064138)
54. RA Nash JH Antin C Karanes, et al. 2000 Phase 3 study comparing methotrexate and Tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 96 2062 2068 10979948
55. E Kansu T Gooley MED Flowers, et al. 2001 Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial Blood 98 3868 3870 10.1182/blood.V98.13.3868 11739201
56. G Strauss W Osen KM Debatin 2002 Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs Clin Exp Immunol 128 255 266 10.1046/j.1365-2249.2002.01777.x 11985515 (Pubitemid 34534038)
57. L Luznik EJ Fuchs AR Chen, et al. 2007 Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT) Biol Blood Marrow Transplant 13 2 Suppl 4 10.1016/j.bbmt.2006.12.008
58. RA Brodsky L Luznik J Bolanos-Meade, et al. 2008 Reduced intensity: HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases Bone Marrow Transplant 42 523 527 10.1038/bmt.2008.203 18622413
59. G Hutter D Nowak M Mossner, et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 692 698 10.1056/NEJMoa0802905 19213682